Comparative Pharmacology
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus VECURONIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATRACURIUM BESYLATE PRESERVATIVE FREE versus VECURONIUM BROMIDE.
ATRACURIUM BESYLATE PRESERVATIVE FREE vs VECURONIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at nicotinic cholinergic receptors at the neuromuscular junction, preventing depolarization and muscle contraction. Degraded via Hofmann elimination (non-enzymatic) and ester hydrolysis.
Competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine binding and muscle contraction.
0.4-0.5 mg/kg IV bolus for intubation; maintenance: 0.08-0.1 mg/kg IV every 15-25 min or continuous infusion 5-10 mcg/kg/min
IV bolus: 0.08-0.1 mg/kg for intubation; maintenance: 0.01-0.015 mg/kg every 12-15 minutes as needed or continuous infusion 0.05-0.1 mg/kg/hour.
None Documented
None Documented
Terminal elimination half-life of atracurium is approximately 20 minutes (range 15-35 min) in healthy adults; clinically, this short half-life correlates with rapid spontaneous recovery without the need for reversal agents, though prolonged in hypothermia or acidosis.
Terminal elimination half-life: 1.2-1.9 hours (65-115 minutes). Clinically, recovery from neuromuscular blockade is faster than with pancuronium; prolonged in renal and hepatic impairment.
Primarily via Hofmann elimination (non-enzymatic degradation) and ester hydrolysis; renal excretion accounts for less than 10% unchanged, with biliary/fecal elimination minimal. Approximately 40% as laudanosine and other metabolites via urine, with laudanosine further metabolized and renally excreted.
Primarily renal (40-60% unchanged in urine within 24 hours); biliary/fecal elimination accounts for <20%. Approximately 10-20% as 3-desacetylvecuronium (active metabolite) in urine.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker